Healio

Once-monthly octreotide provides sustained acromegaly control with fewer injections

Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...
ascopubs.org

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
Nasdaq

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
Yahoo Finance

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Monthly Prescribing Reference

Long-Acting Octreotide Therapy Gets Orphan Drug Status for Polycystic Liver Disease

CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...
The New England Journal of Medicine

Octreotide Therapy for Tumor-Induced Osteomalacia

We describe an adult man who had hypophosphatemic osteomalacia for several years before an octreotide scan revealed a mesenchymal tumor in his left thigh. Moreover, subcutaneous administration of ...
ascopubs.org

Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome

CONCLUSION: Once octreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide. A starting dose of 20 mg of ...
Healio

Octreotide in the treatment of chemotherapy-induced diarrhea

Please provide your email address to receive an email when new articles are posted on . Diarrhea in cancer patients is common and can result from different treatments and toxicities. These include ...
FierceBiotech

PRESS RELEASE: Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial

Company Plans to Initiate Phase III Program in First Half of 2008 LEXINGTON, Mass., Nov. 28 -- Indevus Pharmaceuticals, Inc. today announced positive results from its Phase II octreotide implant trial ...
Nature

New therapeutic agents for acromegaly

Available medical therapies for acromegaly are limited by moderate and variable efficacy, the need for life-long monthly intramuscular and/or deep subcutaneous depot, or thrice-daily subcutaneous ...
Monthly Prescribing Reference

Presence of Glass Particles Prompts Recall of Octreotide Acetate Injection

Syringe and Vials To date, the Company has not received any reports of adverse reactions related to this recall. Mylan Institutional LLC, a Viatris Company, has voluntarily recalled 1 lot of ...
Nasdaq

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...